Fate hits reset as J&J cell therapy deal collapses, slashing pipeline and head count to stretch cash

Fate Therapeutics has begun 2023 with a big reset of its business. Having ended its collaboration with Johnson & Johnson, the cell therapy biotech has decided to slash its head count and stop multiple clinical development programs to stretch out its cash runway.